Anika Therapeutics raised its full-year 2026 guidance, now projecting total company revenue growth of 5% to 10% and an adjusted EBITDA margin of 13% to 17%, up from a prior margin expectation of 5% to 10%. The company reported second-quarter total revenue of $32.6 million, a 16% year-over-year increase, with commercial channel revenue growing 17% to $13.9 million and international revenue reaching a record $12.6 million, up 22%. Gross margin expanded to 65% from 51% a year earlier, and adjusted EBITDA hit $7.1 million, representing a 22% margin. Management said the mid-60s gross margin level is sustainable, driven by operational improvements, while noting that OEM pricing remains a headwind offset by volume. For 2027, Anika adopted a new revenue guidance practice that excludes unapproved products, removing a previously implied $3 million of U.S. Hyalofast sales, and still expects total company revenue growth of 0% to 5%.
Anika Therapeutics IncRaised 2026 revenue growth outlook to 5%-10% and adjusted EBITDA margin to 13%-17%, with strong Q2 results showing 16% revenue growth and 22% EBITDA margin.